dc.contributor.author | Ghazaly, EA | en_US |
dc.contributor.author | Rizzuto, I | en_US |
dc.contributor.author | Gabra, H | en_US |
dc.contributor.author | Habib, NA | en_US |
dc.contributor.author | Leonard, RCF | en_US |
dc.contributor.author | Wasan, H | en_US |
dc.contributor.author | McGuigan, C | en_US |
dc.contributor.author | Blagden, SP | en_US |
dc.date.accessioned | 2016-02-29T12:26:34Z | |
dc.date.issued | 2014-05-20 | en_US |
dc.identifier.issn | 0732-183X | en_US |
dc.identifier.uri | http://meetinglibrary.asco.org/content/149421-156 | |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/11296 | |
dc.description | . Clinical trial information: NCT01621854 | en_US |
dc.language.iso | en | en_US |
dc.title | ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors | en_US |
dc.type | Conference Proceeding | |
dc.rights.holder | American Society of Clinical Oncology | |
dc.identifier.doi | 10.1200/jco.2014.32.15_suppl.2531 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358613202796&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 15 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 32 | en_US |